Haematology Flashcards
What is myeloma?
Cancer of plasma B lymphocytes.
Pathophysiology of myeloma
Excess production of monoclonal immunoglobulins known as paraproteins by the plasma cells.
Which paraproteins are most commonly produced by myelomas?
IgG and IgA.
What are the types of light chains that can make up immunoglobulins?
Kappa and gamma light chains
Clinical presentation of myeloma
Hypercalcaemia
Renal impairment - nephrotic syndrome (thirst)
Normocytic normochromic anaemia, neutropaenia/thrombocytopaenia
Back pain due to lytic bone lesions.
Hyperviscosity of blood.
What causes hypercalacemia and lytic bone lesions in myeloma?
Malignant plasma cells release factors like RANK ligand which stimulate osteoclast activity increasing bone resorption.
What causes nephrotic syndrome in myeloma?
Increased light chain presence causes deposition in renal tubules causing impairment.
Investigation of myeloma
FBC - pancytopaenia
U + E - hypercalcaemia
Blood film - rouleaux formation
Serum electrophoresis
CT/MRI/X-ray - lytic bone lesions
Urinalysis - Bens Jones proteins
Bone marrow trephine biopsy - DIAGNOSTIC
What would the FBC reveal in myeloma?
Low haemoglobin, platelets, neutrophils.
What would a blood film reveal in myeloma?
Rouleaux formation - linear aggregates of erythrocytes that occur when there are increased plasma protein levels.
What would the ESR and creatinine be in myeloma?
Both would be high.
What is serum electrophoresis?
Separates immunoglobulins by mass and charge to identify abnormal bands and immune paresis
Usually where is a bone marrow biopsy taken?
Iliac crest (anterior or posterior).
What can a bone marrow biopsy show with myeloma?
Infiltration by plasma cells.
What would U + E reveal in myeloma?
Hypercalcaemia,
What are the clinical stages of myeloma?
Monoclonal Gammopathy of Undetermined Significance (MGUS)
Smouldering Myeloma
Symptomatic Myeloma
Features of MGUS
Paraprotein<30g/dl, <10% plasma cells in the bone marrow, no related organ or tissue impairment (ROTI), no evidence of amyloid or other lymphoproliferative disorder (LPD)
Features of smouldering myeloma
Paraprotein >30g/l and/or >10% plasma cells in BM, no ROTI (relative organ or tissue impairment)
Features of symptomatic myeloma
Paraprotein > 30 g/l and/or >10% plasma cells in BM
Evidence of related organ or tissue impairment (ROTI) or amyloid
First line management of myeloma
Bortezomib + dexamethasone
Chemotherapy + bisphosphonates
Management to prevent myeloma bone disease
Zoledronic acid
Pharmacodynamics of bortezomib
Proteasome inhibitor
Pharmacodynamics of zoledronic acid
Bisphosphonates - prevent osteoclast activity and bone resorption.
What long term therapy can be given for myeloma patietns
Chemotheraphy, stem cell transplant